Form 4: ADMA Biologics COO Exercises Stock Options, Adjusts Equity Holdings
Insider Transaction Report
ADMA Biologics' Chief Operating Officer and SVP of Compliance, Kaitlin M. Kestenberg-Messina, reported the exercise of employee stock options and subsequent share disposition for tax purposes.
Summary
- Kaitlin M. Kestenberg-Messina, COO and SVP, Compliance of ADMA Biologics, Inc., acquired 2,500 shares of Common Stock through the exercise of an employee stock option at an exercise price of $8.98 per share on July 30, 2025.
- Concurrently, 1,208 shares of Common Stock were disposed of at a price of $18.59 per share to satisfy mandatory tax withholding requirements and cover the option exercise price; this was not an open market sale.
- Following these transactions, Kaitlin M. Kestenberg-Messina beneficially owns 488,690 shares of Common Stock.
- The total beneficial ownership includes 194,166 directly owned shares and 294,524 unvested Restricted Stock Units (RSUs) from various grants between March 2022 and February 2025, vesting over four years.
Sentiment
Score: 5
Explanation: The filing details a routine insider transaction involving the exercise of stock options and shares withheld for tax, which is a standard compensation event and does not reflect significant positive or negative operational news.
Positives
- The reporting person, a key executive, continues to hold a substantial equity stake in the company, aligning management interests with shareholders.
Negatives
- A portion of shares (1,208) was disposed of to cover tax obligations and the option exercise price, which is a standard practice but reduces the direct share count.
Future Outlook
The filing does not provide any forward-looking statements or guidance regarding the company's operational or financial performance.
Industry Context
This filing is a routine insider transaction report, common across all publicly traded companies, and does not provide specific insights into broader industry trends or competitive dynamics within the biologics sector.
Related Party Transactions
- The exercise of employee stock options by a company officer is a related party transaction, representing equity compensation from the issuer to an insider.
Stakeholder Impact
- Shareholders gain transparency into the equity holdings and compensation activities of a key executive.
- The reporting person's equity stake remains substantial, aligning their financial interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 07/30/2015 | Grant date of the employee stock option for 2,500 shares. |
| 03/07/2022 | Grant date for 10,000 unvested RSUs. |
| 03/06/2023 | Grant date for 47,500 unvested RSUs. |
| 07/24/2023 | Grant date for 15,000 unvested RSUs. |
| 04/01/2024 | Grant date for 144,240 unvested RSUs. |
| 02/19/2025 | Grant date for 77,784 unvested RSUs. |
| 07/30/2025 | Transaction date for the exercise of 2,500 employee stock options and disposition of 1,208 shares for tax withholding. |
| 08/01/2025 | Signature date of the Form 4 filing. |
Keywords
ADMA Biologics, ADMA, Form 4, Insider Transaction, Stock Option Exercise, Equity Compensation, Beneficial Ownership, Kaitlin M. Kestenberg-Messina
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.